Initial pathological responses of second-generation everolimus-eluting stents implantation in Japanese coronary arteries: Comparison with first-generation sirolimus-eluting stents

Kawakami, Rika; Hao, Hiroyuki; Imanaka, Tadayuki; Shibuya, Masabumi; Ueda, Yasunori; Tsujimoto, Masahiko; Ishibashi‐Ueda, Hatsue; Hirota, Seiichi

doi:10.1016/j.jjcc.2017.11.009

Cited by 8 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-analysis studies confirmed a lower target-lesion revascularization and incidence of stent thrombosis with newer-generation devices as compared to 1st generation DES and BMS [26,27]. The safety profile of second generation DES was also confirmed by intravascular imaging [28], angioscopy and pathology studies confirming improved stent coverage by neoendothelium associated with less aggregates of red blood cells, less peri-strut fibrin deposition, and a lower inflammation score [28,29]. Further evolutions to improve the biocompatibility of implants included the development of antithrombotic polymers (so-called fluoropassivation [25]), bioresorbable polymers (which however do not seem to improve significantly patients outcomes [30]), and completely bioresorbable scaffolds (whose mechanical characteristics, particularly strut thickness however represented a limitation [13,31,32]).…”

Section: Stent Complications and Stent Pathology Among Different Device Generationsmentioning

confidence: 83%

Vascular Wall Reactions to Coronary Stents—Clinical Implications for Stent Failure

Gori

2021

Life

View full text Add to dashboard Cite

Coronary stents belong to the most commonly implanted devices worldwide. A number of different types of stent exist, with very different mechanical and biochemical characteristics that influence their interactions with vascular tissues. Inappropriate inflammatory reactions are the major cause of the two major complications that follow implantation of stents in a percentage as high as 5–20%. It is therefore important to understand these reactions and how different they are among different generations of stents.

show abstract

Section: Stent Complications and Stent Pathology Among Different Device Generationsmentioning

confidence: 83%

Vascular Wall Reactions to Coronary Stents—Clinical Implications for Stent Failure

Gori

2021

Life

View full text Add to dashboard Cite

show abstract

“…Recently, the second-generation DES, including Xience/Promus everolimus- eluting stent, which consists of a thin strut platform coated with durable fluorinated copolymer and everolimus, were be in widespread use. In several pathological studies 34 , 35 ) , the second-generation DES showed greater strut coverage with less inflammation, less fibrin deposition, and less late and very late stent thrombosis compared with the first-generation DES. In our present study, there were no differences in plasma neopterin levels between patients with cardiovascular events and those without them in the first-generation DES.…”

Section: Discussionmentioning

confidence: 98%

Neopterin and Cardiovascular Events Following Coronary Stent Implantation in Patients with Stable Angina Pectoris

Yoshiyama

Sugioka

Naruko

et al. 2018

JAT

View full text Add to dashboard Cite

Aim: Neopterin is an activation marker for monocytes/macrophages. We prospectively investigated the predictive value of plasma neopterin levels on 2-year and long-term cardiovascular events in patients with stable angina pectoris (SAP) undergoing coronary stent implantation.Methods: We studied 123 consecutive patients with SAP who underwent primary coronary stenting (44 patients with bare metal stent: BMS group and 79 with drug-eluting stent: DES group). Plasma neopterin levels were measured on admission using HPLC. Moreover, one frozen coronary artery specimen after DES and three frozen coronary specimens after BMS were obtained by autopsy or endarterectomy, followed by immunohistochemical staining for neopterin.Results: Plasma neopterin levels were significantly higher in patients with cardiovascular events than in those without them (P < 0.001). In subgroup analyses, higher levels of plasma neopterin in patients with cardiovascular events (P < 0.001) and a positive correlation between neopterin levels and late lumen loss after stenting (P = 0.008) were observed in the BMS group but not in the DES group (P = 0.53 and P = 0.17, respectively). In long-term cardiovascular events, multivariate Cox regression analysis identified the significance of the high-neopterin group as independent determinants of cardiovascular events (hazard ratio, 2.225; 95% CI, 1.283–3.857; P = 0.004). Immunohistochemical staining showed abundant neopterin-positive macrophages in the neointima after BMS implantation but no neopterin-positive macrophages in the neointima after DES implantation.Conclusion: These findings suggest that neopterin is associated with cardiovascular events after coronary stent implantation in patients with SAP. However, there might be a strong association between neopterin and cardiovascular events after BMS but not after DES in these patients.

show abstract

“…The surge in interest in “Everolimus-eluting stents” highlights a focus on this second-generation drug-eluting stent, utilizing everolimus, categorized as an immunosuppressive drug and belonging to the class of mTOR (mammalian target protein of rapamycin) inhibitors, to counteract vascular endothelial cell proliferation and reduce the risk of ISR ( 113 – 115 ). Everolimus-eluting stents offer diverse designs and materials, facilitating comparisons with other stent types in long-term prognosis studies ( 85 , 116 – 118 ).…”

Section: Discussionmentioning

confidence: 99%

Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis

Zeng,

Xu,

Deng

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Drug-eluting stents (DES) play a crucial role in treating coronary artery disease (CAD) by preventing restenosis. These stents are coated with drug carriers that release antiproliferative drugs within the vessel. Over the past two decades, DES have been employed in clinical practice using various materials, polymers, and drug types. Despite optimizations in their design and materials to enhance biocompatibility and antithrombotic properties, evaluating their long-term efficacy and safety necessitates improved clinical follow-up and monitoring. To delineate future research directions, this study employs a bibliometric analysis approach. We comprehensively surveyed two decades' worth of literature on DES for CAD using the Web of Science Core Collection (WOSCC). Out of 5,778 articles, we meticulously screened them based on predefined inclusion and exclusion criteria. Subsequently, we conducted an in-depth analysis encompassing annual publication trends, authorship affiliations, journal affiliations, keywords, and more. Employing tools such as Excel 2021, CiteSpace 6.2R3, VOSviewer 1.6.19, and Pajek 5.17, we harnessed bibliometric methods to derive insights from this corpus. Analysis of annual publication data indicates a recent stabilisation or even a downward trend in research output in this area. The United States emerged as the leading contributor, with Columbia University and CRF at the forefront in both publication output and citation impact. The most cited document pertained to standardized definitions for clinical endpoints in coronary stent trials. Our author analysis identifies Patrick W. Serruys as the most prolific contributor, underscoring a dynamic exchange of knowledge within the field.Moreover, the dual chart overlay illustrates a close interrelation between journals in the “Medicine,” “Medical,” and “Clinical” domains and those in “Health,” “Nursing,” and “Medicine.” Frequently recurring keywords in this research landscape include DES coronary artery disease, percutaneous coronary intervention, implantation, and restenosis. This study presents a comprehensive panorama encompassing countries, research institutions, journals, keyword distributions, and contributions within the realm of DES therapy for CAD. By highlighting keywords exhibiting recent surges in frequency, we elucidate current research hotspots and frontiers, thereby furnishing novel insights to guide future researchers in this evolving field.

show abstract

Initial pathological responses of second-generation everolimus-eluting stents implantation in Japanese coronary arteries: Comparison with first-generation sirolimus-eluting stents

Abstract: Histopathological analysis showed advanced healing process in 2nd DES compared with 1st DES lesions. These results are consistent with clinical beneficial outcome of 2nd DES implantation.

Cited by 8 publications

References 37 publications

Vascular Wall Reactions to Coronary Stents—Clinical Implications for Stent Failure

Vascular Wall Reactions to Coronary Stents—Clinical Implications for Stent Failure

Neopterin and Cardiovascular Events Following Coronary Stent Implantation in Patients with Stable Angina Pectoris

Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis

Contact Info

Product

Resources

About